• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session

    11/22/22 1:16:51 PM ET
    $A
    $AENZ
    $AEO
    $AGBA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Engineering & Construction
    Industrials
    Get the next $A alert in real time by email

    Gainers

    • Palisade Bio, Inc. (NASDAQ:PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery.
    • Cosmos Holdings Inc. (NASDAQ:COSM) rose 52% to $0.2656 after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda.
    • Aenza S.A.A. (NYSE:AENZ) gained 42.3% to $3.49.
    • ObsEva SA (NASDAQ:OBSV) shares climbed 31.3% to $0.2175 after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million.
    • Bonso Electronics International Inc. (NASDAQ:BNSO) shares climbed 30.5% to $4.0532.
    • FOXO Technologies Inc. (NYSE:FOXO) jumped 23% to $0.6001. Foxo Technologies, said effective November 14, 2022, Jon Sabes has been terminated as CEO and Chairman of board of company.
    • Grindr Inc. (NYSE:GRND) gained 21.3% to $23.91 after dropping 46% on Monday.
    • Charah Solutions, Inc. (NYSE:CHRA) jumped 21.1% to $1.0628. Charah Solutions recently reported mixed Q3 results.
    • Cingulate Inc. (NASDAQ:CING) gained 20.3% to $0.8313. Maxim Group initiated coverage on Cingulate with a Buy rating and announced a price target of $3.
    • Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) surged 20.3% to $0.6743. Cyclerion said it concluded the unsolicited proposal received on November 20 was “not in the best interest of the company.”
    • Biodesix, Inc. (NASDAQ:BDSX) jumped 20% to $1.5600. Biodesix 10% owner Jack Schuler acquired a total of 8,695,652 shares at an average price of $1.15.
    • WW International, Inc. (NASDAQ:WW) gained 17.4% to $4.2650. Sima Sistani, Chief Executive Officer at WW International, reported a large insider buy on November 21, according to a new SEC filing.
    • Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) rose 17.3% to $0.6571 after gaining around 8% on Monday.
    • American Eagle Outfitters, Inc. (NYSE:AEO) gained 16.5% to $15.15 after the company reported better-than-expected Q3 GAAP EPS and sales results.
    • Burlington Stores, Inc. (NYSE:BURL) jumped 16.4% to $183.55 after the company reported Q3 financial results and issued guidance.
    • Draganfly Inc. (NASDAQ:DPRO) gained 15.3% to $1.06. Draganfly has been selected by PromoDrone to provide its Public Safety technology to the PromoDrone platform for Emergency Management.
    • Elevation Oncology, Inc. (NASDAQ:ELEV) rose 15.2% to $1.08.
    • Warner Music Group Corp. (NASDAQ:WMG) jumped 14.8% to $30.99. Warner Music Group reported fourth-quarter FY22 revenue growth of 8.8% year-on-year to $1.497 billion, beating the consensus of $1.42 billion.
    • Abercrombie & Fitch Co. (NYSE:ANF) gained 14.8% to $21.38 after the company reported better-than-expected Q3 EPS and sales results.
    • TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) jumped 11.4% to $1.3824. TFF Pharmaceuticals recently priced a $10.675 million offering of common stock and warrants.
    • Best Buy Co., Inc. (NYSE:BBY) gained 11.2% to $78.77 after the company reported better-than-expected Q3 EPS and sales results.
    • Maximus, Inc. (NYSE:MMS) surged 9.6% to $66.35 after the company reported better-than-expected Q4 EPS and sales results. The company also issued FY23 EPS and sales guidance above analyst estimates.
    • Angel Pond Holdings Corporation (NYSE:POND) gained 9% to $10.63.
    • Nexalin Technology, Inc. (NASDAQ:NXL) rose 8.2% to $2.2192 after surging around 14% on Monday.
    • Agilent Technologies, Inc. (NYSE:A) gained 6.7% to $154.95 after the company reported better-than-expected Q4 EPS and sales results.
    • First Wave BioPharma, Inc. (NASDAQ:FWBI) rose 6.3% to $0.7219. First Wave BioPharma reported a private placement.

     

    Losers

    • Eqonex Limited (NASDAQ:EQOS) fell 27.9% to $0.1514 after dipping around 24% on Monday.
    • Perfect Corp. (NYSE:PERF) fell 22% to $6.75. Goldman Sachs, on Monday, initiated coverage on Perfect with a Neutral rating and announced a price target of $7.8.
    • Agora, Inc. (NASDAQ:API) dropped 21% to $2.6450 after the company posted downbeat Q3 results and issued weak FY22 sales forecast.
    • Actinium Pharmaceuticals, Inc. (NYSE:ATNM) declined 19.9% to $9.44.
    • MacroGenics, Inc. (NASDAQ:MGNX) shares tumbled 18.9% to $5.16 after Cowen & Co. downgraded the stock from Outperform to Market Perform.
    • VIQ Solutions Inc. (NASDAQ:VQS) fell 17.8% to $0.2547.
    • GDS Holdings Limited (NASDAQ:GDS) dipped 17.1% to $11.45.
    • EUDA Health Holdings Limited (NASDAQ:EUDA) fell 16.9% to $3.14 after dipping 15% on Monday.
    • Jack in the Box Inc. (NASDAQ:JACK) fell 16.4% to $70.98 after the company issued soft FY23 guidance.
    • Mesa Laboratories, Inc. (NASDAQ:MLAB) declined 15.7% to $155.25 after the company announced its Clinical Genomics Division customer, Sema4, will exit the reproductive health screening business. Sema4 informed the company it will reduce the quantity of orders in Q3.
    • Dycom Industries, Inc. (NYSE:DY) fell 15.5% to $92.63 after the company reported Q3 earnings results.
    • WiSA Technologies, Inc. (NASDAQ:WISA) dropped 14.8% to $0.22.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) shares fell 14.7% to $0.4004 in pre-market trading after jumping 10% on Monday.
    • Noah Holdings Limited (NYSE:NOAH) dipped 14.4% to $12.80 following Q3 results.
    • iQIYI, Inc. (NASDAQ:IQ) fell 13.8% to $2.4450 following Q3 results.
    • Satixfy Communications Ltd. (NYSE:SATX) dropped 13.4% to $26.98.
    • Gamida Cell Ltd. (NASDAQ:GMDA) fell 12.8% to $1.5525 after the company issued a regulatory update on Omidubicel. The company said it received extension of Omidubicel PDUFA Date from Jan. 30, 2023 to May 1, 2023 as the FDA issued information request.
    • Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) dropped 12.5% to $2.16.
    • Construction Partners, Inc. (NASDAQ:ROAD) fell 11.8% to $28.65 after reporting Q4 results.
    • AGBA Group Holding Limited (NASDAQ:AGBA) fell 11.7% to $5.58. AGBA Acquisition Limited recently completed its business combination with TAG Holdings Limited.
    • Movado Group, Inc. (NYSE:MOV) dropped 11% to $29.81 after the company posted downbeat quarterly sales and lowered FY23 sales forecast.
    • Central Garden & Pet Company (NASDAQ:CENTA) dipped 10.6% to $37.50 following weak quarterly results.
    • Dollar Tree, Inc. (NASDAQ:DLTR) fell 9.9% to $148.97 after the company reported Q3 earnings results.
    • Siyata Mobile Inc. (NASDAQ:SYTA) fell 9.1% to $0.1765 after jumping 26% on Monday.
    • Canoo Inc. (NASDAQ:GOEV) fell 9.1% to $1.0550. The company recently posted a narrower-than-expected quarterly loss.
    • Chico's FAS, Inc. (NYSE:CHS) dropped 6.7% to $6.64 after the company issued weak Q4 forecast.
    • Zoom Video Communications, Inc. (NASDAQ:ZM) fell 6% to $75.49 after the company reported better-than-expected results, but issued weak guidance.
    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $AENZ
    $AEO
    $AGBA

    CompanyDatePrice TargetRatingAnalyst
    Dollar Tree Inc.
    $DLTR
    2/17/2026$165.00Neutral → Buy
    Rothschild & Co Redburn
    Dollar Tree Inc.
    $DLTR
    2/13/2026$95.00Market Perform → Underperform
    BMO Capital Markets
    Zoom Communications Inc.
    $ZM
    2/5/2026$115.00Peer Perform → Outperform
    Wolfe Research
    Best Buy Co. Inc.
    $BBY
    2/2/2026$76.00Overweight → Neutral
    Analyst
    Warner Music Group Corp.
    $WMG
    1/27/2026$38.00Buy
    MoffettNathanson
    Dycom Industries Inc.
    $DY
    1/22/2026$510.00Buy
    Guggenheim
    Dollar Tree Inc.
    $DLTR
    1/21/2026Neutral → Underperform
    BNP Paribas Exane
    Abercrombie & Fitch Company
    $ANF
    1/21/2026$135.00Neutral → Buy
    Citigroup
    More analyst ratings

    $A
    $AENZ
    $AEO
    $AGBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dollar Tree upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Dollar Tree from Neutral to Buy and set a new price target of $165.00

    2/17/26 8:01:44 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Dollar Tree downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Dollar Tree from Market Perform to Underperform and set a new price target of $95.00

    2/13/26 8:27:52 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Zoom Communications upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Zoom Communications from Peer Perform to Outperform and set a new price target of $115.00

    2/5/26 6:52:31 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    $A
    $AENZ
    $AEO
    $AGBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Draganfly Welcomes Lieutenant-General (Ret'd) Michel Gauthier to Military Advisory Board in Support of Canada's Defence Industrial Strategy

    Ottawa, ON, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ:DPRO, CSE:DPRO, FSE: 3U8A)) ("Draganfly" or the "Company"), an award-winning developer of drone solutions, software, and robotics, today announced the appointment of Lieutenant-General (Ret'd) Michel Gauthier to its Military Advisory Board. The appointment comes as Canada advances its renewed Defence Industrial Strategy, a national framework focused on strengthening sovereign defence production, accelerating innovation, modernizing procurement, and reducing reliance on foreign supply chains. Lieutenant-General Gauthier brings more than 36 years of distinguished service with the Canadian Armed Forces. He served as Comman

    2/20/26 8:30:00 AM ET
    $DPRO
    Aerospace
    Industrials

    Biglari Capital: 18% decline in Jack in the Box Share Price after Q1 Earnings

    Continued Deterioration of JACK's Share Price and Operating Metrics Further Warrants Voting Against the Election of David GoebelSAN ANTONIO, Feb. 20, 2026 /PRNewswire/ -- Biglari Capital Corp. ("Biglari Capital"), the largest shareholder of Jack in the Box Inc. (NASDAQ:JACK) with a 9.86% ownership stake, today issued the following statement: Disastrous Quarterly Results Confirm the Need for Urgent Action For any shareholder still weighing whether Chairman Goebel's continued presence poses a real risk, JACK's first-quarter fiscal 2026 earnings provide the answer — in case the last 17 years were not convincing enough. The results are terrible by any measure:Same-store sales declined 6.7% syste

    2/20/26 8:00:00 AM ET
    $JACK
    Restaurants
    Consumer Discretionary

    Burlington Stores, Inc. Announces Fourth Quarter and Fiscal Year 2025 Earnings Release Date, Conference Call and Webcast

    BURLINGTON, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Burlington Stores, Inc. (NYSE:BURL), a nationally recognized off-price retailer of high-quality, branded apparel, footwear, accessories, and merchandise for the home at everyday low prices, will release its fourth quarter and fiscal year 2025 results before the U.S. stock market opens on Thursday, March 5, 2026. The Company will also hold a conference call to discuss results at 8:30 a.m. (Eastern Time) that day. The U.S. toll free dial-in for the conference call is 1-800-715-9871 (passcode: 3196665) and the international dial-in number is 1-646-307-1963. A live webcast of the conference call will also be available on the investor relatio

    2/19/26 4:15:00 PM ET
    $BURL
    Department/Specialty Retail Stores
    Consumer Discretionary

    $A
    $AENZ
    $AEO
    $AGBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    CEO & President Caswell Bruce bought $249,081 worth of shares (3,175 units at $78.45), increasing direct ownership by 0.98% to 328,013 units (SEC Form 4)

    4 - MAXIMUS, INC. (0001032220) (Issuer)

    2/11/26 4:31:50 PM ET
    $MMS
    Real Estate

    $A
    $AENZ
    $AEO
    $AGBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Haley John J gifted 32,764 shares and received a gift of 32,764 shares (SEC Form 4)

    4 - MAXIMUS, INC. (0001032220) (Issuer)

    2/19/26 4:30:31 PM ET
    $MMS
    Real Estate

    Chief Financial Officer Wolfe Kristin was granted 10,048 shares, increasing direct ownership by 45% to 32,237 units (SEC Form 4)

    4 - Burlington Stores, Inc. (0001579298) (Issuer)

    2/19/26 4:15:27 PM ET
    $BURL
    Department/Specialty Retail Stores
    Consumer Discretionary

    Chief Executive Officer O Sullivan Michael B was granted 54,768 shares, increasing direct ownership by 40% to 191,742 units (SEC Form 4)

    4 - Burlington Stores, Inc. (0001579298) (Issuer)

    2/19/26 4:15:18 PM ET
    $BURL
    Department/Specialty Retail Stores
    Consumer Discretionary

    $A
    $AENZ
    $AEO
    $AGBA
    SEC Filings

    View All

    SEC Form DEFR14A filed by Jack In The Box Inc.

    DEFR14A - JACK IN THE BOX INC (0000807882) (Filer)

    2/20/26 4:35:50 PM ET
    $JACK
    Restaurants
    Consumer Discretionary

    SEC Form 6-K filed by Draganfly Inc.

    6-K - Draganfly Inc. (0001786286) (Filer)

    2/20/26 8:31:56 AM ET
    $DPRO
    Aerospace
    Industrials

    SEC Form DEFA14A filed by Jack In The Box Inc.

    DEFA14A - JACK IN THE BOX INC (0000807882) (Filer)

    2/19/26 3:09:19 PM ET
    $JACK
    Restaurants
    Consumer Discretionary

    $A
    $AENZ
    $AEO
    $AGBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 18, 2024 - FDA Roundup: June 18, 2024

    For Immediate Release: June 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for input about patient safety associated with certain medical software functions excluded from the medical device definition. This input will help the FDA develop the 2024 report on the risks and benefits to health of non-devic

    6/18/24 3:16:28 PM ET
    $DLTR
    $AMGN
    Department/Specialty Retail Stores
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for MARGENZA issued to MACROGENICS INC

    Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

    5/29/23 4:45:45 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $A
    $AENZ
    $AEO
    $AGBA
    Financials

    Live finance-specific insights

    View All

    Burlington Stores, Inc. Announces Fourth Quarter and Fiscal Year 2025 Earnings Release Date, Conference Call and Webcast

    BURLINGTON, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Burlington Stores, Inc. (NYSE:BURL), a nationally recognized off-price retailer of high-quality, branded apparel, footwear, accessories, and merchandise for the home at everyday low prices, will release its fourth quarter and fiscal year 2025 results before the U.S. stock market opens on Thursday, March 5, 2026. The Company will also hold a conference call to discuss results at 8:30 a.m. (Eastern Time) that day. The U.S. toll free dial-in for the conference call is 1-800-715-9871 (passcode: 3196665) and the international dial-in number is 1-646-307-1963. A live webcast of the conference call will also be available on the investor relatio

    2/19/26 4:15:00 PM ET
    $BURL
    Department/Specialty Retail Stores
    Consumer Discretionary

    Jack in the Box Inc. Reports First Quarter 2026 Earnings

    Jack in the Box same-store sales of (6.7%) Diluted EPS from continuing operations of $0.75 and Operating EPS of $1.00 Jack in the Box Inc. (NASDAQ:JACK) announced financial results for the first quarter ended January 18, 2026. The Company completed the sale of Del Taco Holdings Inc. ("Del Taco") on December 22, 2025. The Del Taco results are included in discontinued operations for all periods presented. "Our results for the quarter were in line with our expectations. We remain focused on the fundamentals, simplifying the business, and delivering on our 'JACK on Track' commitments as we build a stronger foundation for sustainable growth," said Lance Tucker, Jack in the Box Chief Exec

    2/18/26 4:05:00 PM ET
    $JACK
    Restaurants
    Consumer Discretionary

    Biglari Capital Announces Two of Three Leading Proxy Advisory Firms Urge Shareholders to Vote AGAINST Jack in the Box Chairman David Goebel

    Glass Lewis Cites "Exceptionally Poor" Performance and "Muted Commitment to Tangible Culpability" in Recommending AGAINST Goebel Egan-Jones Recommends AGAINST the Election of David Goebel, Stating "Urgent Change at the Board Level Is Warranted"Glass Lewis and Egan-Jones Analyses Support Biglari Capital's Thesis ISS Stands Alone in Defending the Status Quo Despite Catastrophic Value Destruction, a Failed Del Taco Acquisition, and Unaddressed Deep-Rooted Governance Concerns SAN ANTONIO, Feb. 17, 2026 /PRNewswire/ -- Biglari Capital Corp. ("Biglari Capital"), the largest shareholder of Jack in the Box Inc. (NASDAQ:JACK), with a 9.86% ownership stake, today issued the following statement regardi

    2/17/26 1:18:00 PM ET
    $JACK
    Restaurants
    Consumer Discretionary

    $A
    $AENZ
    $AEO
    $AGBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by iQIYI Inc.

    SC 13D/A - iQIYI, Inc. (0001722608) (Subject)

    12/4/24 8:11:53 AM ET
    $IQ
    Consumer Electronics/Video Chains
    Consumer Discretionary

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc.

    SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

    11/19/24 4:05:58 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $AENZ
    $AEO
    $AGBA
    Leadership Updates

    Live Leadership Updates

    View All

    Draganfly Welcomes Lieutenant-General (Ret'd) Michel Gauthier to Military Advisory Board in Support of Canada's Defence Industrial Strategy

    Ottawa, ON, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ:DPRO, CSE:DPRO, FSE: 3U8A)) ("Draganfly" or the "Company"), an award-winning developer of drone solutions, software, and robotics, today announced the appointment of Lieutenant-General (Ret'd) Michel Gauthier to its Military Advisory Board. The appointment comes as Canada advances its renewed Defence Industrial Strategy, a national framework focused on strengthening sovereign defence production, accelerating innovation, modernizing procurement, and reducing reliance on foreign supply chains. Lieutenant-General Gauthier brings more than 36 years of distinguished service with the Canadian Armed Forces. He served as Comman

    2/20/26 8:30:00 AM ET
    $DPRO
    Aerospace
    Industrials

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leading Independent Proxy Advisory Firm ISS Recommends Jack in the Box Shareholders Vote "FOR" all 10 of the Company's Highly Qualified Director Nominees

    ISS Recommendation Highlights Company's Willingness to Work Constructively with Shareholders and Recent Board Enhancements Jack in the Box Board Urges Shareholders to Vote "FOR" ALL 10 of Jack in the Box's Director Nominees, including David Goebel, Independent Chair of the Jack in the Box Board, on the WHITE Proxy Card Visit www.KeepJackonTrack.com for More Information Jack in the Box Inc. ("Jack in the Box" or the "Company") (NASDAQ:JACK), today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that Jack in the Box shareholders vote "FOR" all 10 of the Company's director nominees, including David Goebel, Independent Chai

    2/17/26 8:00:00 AM ET
    $JACK
    Restaurants
    Consumer Discretionary